Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: DeCode Marks Q1 With Strong Revenue Growth, Narrowed Loss

NEW YORK, May 14 - DeCode said last night that an increase in corporate partnerships helped drive strong first-quarter revenue growth and a narrowed net loss.

 

Total revenue for the period ended March 31 was $9.5 million, an 88-percent increase from the $5.0 million it posted one year ago, the company said.

 

R&D spending for the quarter dipped to just under $18 million from more than $20 million in the first quarter 2002. This, plus 8.4 million new shares issued following DeCode's acquisition of MediChem Life Sciences in late March, helped narrow net loss to $11.2 million, or $.24 per share, from $16.1 million, or $.37 per share, in the year-ago period.

 

DeCode said it had slightly more than $147 million in cash and cash equivalents as of March 31.

 

Click here for more information.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more